Lung Cancer Genomic Testing Market by Technology, Sample Type, Panel Type, End User

Description

List of Tables

[181 Pages Report] The Lung Cancer Genomic Testing Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.07 billion in 2024, at a CAGR 8.00% to reach USD 1.73 billion by 2030.

Global Lung Cancer Genomic Testing Market

KEY MARKET STATISTICS
Base Year [2023]	USD 1.01 billion
Estimated Year [2024]	USD 1.07 billion
Forecast Year [2030]	USD 1.73 billion
CAGR (%)	8%

Lung Cancer Genomic Testing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lung Cancer Genomic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lung Cancer Genomic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Fluorescence In Situ Hybridization
- Next-Generation Sequencing
- Polymerase Chain Reaction
Sample Type
- Liquid Biopsy
- Tissue Biopsy
Panel Type
- Multi-Gene Panel
- Single-Gene Panel
End User
- Diagnostic Laboratories
- Hospitals/Clinics
- Research Organization
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lung Cancer Genomic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lung Cancer Genomic Testing Market?

3. What are the technology trends and regulatory frameworks in the Lung Cancer Genomic Testing Market?

4. What is the market share of the leading vendors in the Lung Cancer Genomic Testing Market?

5. Which modes and strategic moves are suitable for entering the Lung Cancer Genomic Testing Market?

Product Code: MRR-7C31448F0BBE

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Lung Cancer Genomic Testing Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising number of cancer incidences across the world
  - 5.1.1.2. Government initiatives to expand access to lung cancer treatment
  - 5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
- 5.1.2. Restraints
  - 5.1.2.1. High cost of genetic testing services and the lack of reimbursement
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in next-generation genome sequencing
  - 5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulations concerning genetic and molecular testing
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Lung Cancer Genomic Testing Market, by Technology

6.1. Introduction
6.2. Fluorescence In Situ Hybridization
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction

7. Lung Cancer Genomic Testing Market, by Sample Type

7.1. Introduction
7.2. Liquid Biopsy
7.3. Tissue Biopsy

8. Lung Cancer Genomic Testing Market, by Panel Type

8.1. Introduction
8.2. Multi-Gene Panel
8.3. Single-Gene Panel

9. Lung Cancer Genomic Testing Market, by End User

9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals/Clinics
9.4. Research Organization

10. Americas Lung Cancer Genomic Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Lung Cancer Genomic Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Abbott Laboratories
- 14.1.2. Admera Health
- 14.1.3. Agilent Technologies, Inc.
- 14.1.4. BGI
- 14.1.5. CD Genomics
- 14.1.6. CeGaT GmbH
- 14.1.7. Centogene N.V.
- 14.1.8. F. Hoffmann-La Roche AG
- 14.1.9. Illumina, Inc.
- 14.1.10. Laboratory Corporation of America Holdings
- 14.1.11. NeoGenomics Laboratories
- 14.1.12. OncoDNA
- 14.1.13. OPKO Health, Inc.
- 14.1.14. QIAGEN N.V.
- 14.1.15. Quest Diagnostics Incorporated
- 14.1.16. Thermo Fisher Scientific, Inc.
- 14.1.17. Veracyte, Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing